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Comparative transcriptomic profiling of
myxomatous mitral valve disease in the
cavalier King Charles spaniel
G. R. Markby1, V. E. Macrae1, B. M. Corcoran1,2*† and K. M. Summers1,3†
Abstract
Background: Almost all elderly dogs develop myxomatous mitral valve disease by the end of their life, but the
cavalier King Charles spaniel (CKCS) has a heightened susceptibility, frequently resulting in death at a young age
and suggesting that there is a genetic component to the condition in this breed. Transcriptional profiling can
reveal the impact of genetic variation through differences in gene expression levels. The aim of this study was to
determine whether expression patterns were different in mitral valves showing myxomatous degeneration from
CKCS dogs compared to valves from non-CKCS dogs.
Results: Gene expression patterns in three groups of canine valves resulted in distinct separation of normal valves,
diseased valves from CKCS and diseased valves from other breeds; the latter were more similar to the normal valves than
were the valves from CKCS. Gene expression patterns in diseased valves from CKCS dogs were quite different from those
in the valves from other dogs, both affected and normal. Patterns in all diseased valves (from CKCS and other breeds)
were also somewhat different from normal non-diseased samples. Analysis of differentially expressed genes showed
enrichment in GO terms relating to cardiac development and function and to calcium signalling canonical pathway in
the genes down-regulated in the diseased valves from CKCS, compared to normal valves and to diseased valves from
other breeds. F2 (prothrombin) (CKCS diseased valves compared to normal) and MEF2C pathway activation (CKCS
diseased valves compared to non-CKCS diseased valves) had the strongest association with the gene changes. A large
number of genes that were differentially expressed in the CKCS diseased valves compared with normal valves and
diseased valves from other breeds were associated with cardiomyocytes including CASQ2, TNNI3 and RYR2.
Conclusion: Transcriptomic profiling identified gene expression changes in CKCS diseased valves that were not present
in age and disease severity-matched non-CKCS valves. These genes are associated with cardiomyocytes, coagulation and
extra-cellular matrix remodelling. Identification of genes that vary in the CKCS will allow exploration of genetic variation to
understand the aetiology of the disease in this breed, and ultimately development of breeding strategies to eliminate this
disease from the breed.
Keywords: Genes expression, Gene clustering, Gene networks, Myxomatous mitral valve disease, cavalier King Charles
spaniel
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Background
Myxomatous mitral valve disease (MMVD) is very com-
mon in elderly dogs of all genetic backgrounds [1, 2].
The cavalier King Charles spaniel (CKCS) breed has a
particularly high prevalence of myxomatous mitral valve
disease (MMVD), with earlier development and a more
rapid progression to severe end-stage disease compared
to most other dog breeds [3–6]. This breed association
suggests that there is a genetic basis for MMVD in the
CKCS. Interestingly, the CKCS breed exhibits unique
physiological differences from other breeds such as de-
fects in platelet function, macro-thrombocytopenia and
elevated circulating 5-hydroxytryptamine (5HT, also
known as serotonin) levels [7–11]. A rare familial
macro-thrombocytopenia has been found to be associ-
ated with cardiac valvulopathies in children, and there is
evidence to suggest dysregulation of serotonergic signal-
ling might contribute to the aetiopathogenesis of
MMVD in both the dog and human [12]. For example,
rare instances of acquired valvulopathies have been re-
ported in human patients with carcinoid syndrome (ex-
cessive circulating 5HT) and chronic usage of appetite
suppressants and anti-Parkinsonian drugs that target
5HT receptors [13–15]. Furthermore, there is evidence
of enhanced 5HT signalling in both human and canine
MMVD valve tissue and valve interstitial cells (VIC) ex-
posed to tensile strain, and genetic variation in the exons
of the 5HT transporter gene (SLC6A4, also known as
SERT) may be associated with MMVD development in
the Maltese terrier [16, 17]. Changes in expression of the
5HT receptor gene are reported for the canine mitral
valve transcriptome, and in the dog HTR2B expression is
associated with disease progression [18–21]. However,
5HT does not induce disease phenotype in cultured
VICs and expression of 5HT receptor genes is controlled
by TGFβ1 [22]. Nevertheless, taken together, the evi-
dence would suggest that the CKCS has a variant of
MMVD that differs somewhat from other dogs, despite
the end-stage valve pathology and outcome being the
same [23].
For some time it has also been recognised that MMVD
has a high degree of heritability in the CKCS and the
success of breeding programmes increasing the age of
onset support this [5]. One of the only two reported
genome-wide association studies (GWAS) identified two
loci with a total of 31 protein coding genes within these
regions that could be affected, but follow up on these
proteins has not been published [24, 25]. Attempts to
find similar genetic mutations in CKCSs and Dachs-
hunds to those reported for human familial MMVD have
been unsuccessful [26]. While features of the condition
show high heritability in certain breeds, it is unlikely that
a single or small number of genetic variants are
implicated.
There are limited tissue gene expression data for ca-
nine MMVD, but one study reported the transcriptomic
profile of aged CKCS with advanced disease [18]. The
analysis found that the most affected biologically rele-
vant functions were inflammatory/immune response,
cellular movement, cardiovascular development, extra-
cellular matrix organization and epithelial-to-
mesenchymal transition (EMT), not dissimilar to the
one other canine report not involving CKCSs [18, 19].
Of particular note were changes in expression of a range
of cathepsins, matrix metalloproteinases and ADAMTS
(a disintegrin and metalloproteinase with thrombospon-
din motif) family members, important in extracellular
matrix remodelling, and a range of genes involved in
endothelial-to-mesenchymal transition (EndoMT) [18,
27]. More recently we have shown the canine MMVD
valve transcriptome changes progressively as the disease
worsens in a range of dog breeds, but also have identi-
fied by sample-to-sample network analysis that the cava-
lier King Charles spaniel (CKCS) valve transcriptome
was distinct from that seen with non-CKCSs with similar
disease severity (Markby et al., in press; doi: https://doi.
org/10.3389/fgene.2020.00372).
While global transcriptomic profiling of all dogs can
give insight into the possible signalling pathways in-
volved in MMVD pathogenesis, it does not clarify any
breed-specific changes. Considering the prevalence of
MMVD in the CKCS, the physiological differences that
might impact on MMVD pathogenesis and the apparent
differential clustering of gene changes compared to non-
CKCSs, the aim of this study was to compare the mitral
valve transcriptome profile of the CKCS to non-CKCS
with severe to very severe (Whitney grade 3–4) MMVD,
and against the profile of normal non-CKCS young adult
dogs.
Results
Characteristics of the dogs in the study
Details of the animals used in the study are presented in
Table 1. There was no significant difference in age be-
tween the two diseased groups, but both diseased groups
were significantly older than the normal group (P <
0.001). Both sexes were represented in all groups and
gender did not have an effect on gene expression, based
on principal components analysis and network analysis
(Fig. 1a). There were six valves with Grade 3 and 4
MMVD from CKCS and five Grade 3 and 4 valves were
from other breeds (terrier breeds and Border Collies)
(Fig. 1b and c). The normal dogs were Beagles and
mixed breeds (Table 1).
Network analysis of samples
To visualise the expression data, we used the network
visualisation and analysis tool BioLayout (http://
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biolayout.org). Initially we wished to ascertain whether
the samples could be grouped on the basis of disease
status or breed. We therefore created a three dimen-
sional sample-to-sample weighted network graph, based
on a pairwise matrix of Pearson correlation coefficients.
To minimise noise we filtered out low expression genes
(normalised relative expression < 15). The graph was laid
out at a Pearson correlation coefficient threshold of 0.98
(see Methods). This showed that expression patterns of
all grade 3 and 4 samples were separated from the ex-
pression patterns of the normal samples (Fig. 1b), and
there was also a clear separation of CKCS diseased valve
samples away from the non-CKCS diseased samples,
with the non-CKCS diseased valve samples closer to the
normal valves in the network than were the CKCS dis-
eased valves (Fig. 1c). This suggested that the diseased
valves from non-CKCS and CKCS dogs had distinct pat-
terns of gene expression.
To explore the transcriptomic differences between dis-
eased valves from CKCS and other breeds and from
normal valves, we used BioLayout to construct a gene
co-expression network (GCN) [28] from the same ex-
pression data, using a threshold correlation coefficient of
0.9. The analysis included 7247 genes making 20,612
edges. Nodes within the network were then clustered
based on the similarity of expression pattern using the
Table 1 Metadata for valve samples analysed. Whitney gross
pathology grade (0 normal to 4 very severe) was assigned
independently by two of the authors (GRM and BMC).
Breed Gender Age Whitney Grade
Normal
Cross-terrier Male 2 yrs 0
Cross-terrier Male 3 yrs 0
Beagle Male 3 yrs 0
Cross-Staffordshire bull terrier Male 3 yrs 0
Beagle Female 4 yrs 0
Beagle Male 4 yrs 0
Mean Age +/−S.E. 3.1 yrs. +/−0.35
Non-CKCS
Cross-English bull terrier Female 10 yrs 3
West Highland white terrier Male 10 yrs 3
Jack Russel terrier Female 11 yrs 4
Border collie Male 13 yrs 4
Border collie Male 13 yrs 4
Mean Age +/−S.E. 11.4 yrs. +/−0.27
CKCS
Male 12 yrs 3
Male 11 yrs 3
Male 12 yrs 3
Female 10 yrs 3
Male 16 yrs 4
Female 12 yrs 4
Mean Age +/−S.E. 12.5 yrs.+/−0.33
There was no significant difference in age between the CKCS and non-CKCS
group, but there was for both compared to normal group (P < 0.001)
Fig. 1 Sample-to-sample network analysis using BioLayout, showing
relationships between gene expression patterns of mitral valve
samples. Nodes (spheres) represent samples and edges (lines
between samples) show a correlation between the expression
profiles of samples of greater than 0.98. Similar samples are placed
close together in the network. Each image shows the same network
with nodes coloured based on different variables. a. Nodes are
coloured by sex of the dog from which the valve was removed. Red
– female; blue – male. b. Nodes are coloured by grade of MMVD
disease found in the valve. Green − normal valves; Orange – Grade 3
diseased valves; red – Grade 4 diseased valves. c. Samples from
CKCS diseased valves are separated from other samples. Green −
normal valves; blue − non-CKCS diseased valves; dark red − CKCS
diseased valves
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Markov Clustering (MCL) algorithm at an inflation value
of 1.7, as implemented in BioLayout. This is a
hypothesis-free approach, where the number of clusters
is not constrained. In this analysis we reviewed all clus-
ters with at least 5 nodes (probesets with expression pat-
terns correlated at r ≥ 0.9). As we have seen in other
studies [29, 30] there was considerable individual dog-
specific variation and many clusters were driven by high
expression of a subset of genes in a single or small num-
ber of individuals, independent of disease status. These
clusters were not analysed further. However, there were
also clusters showing overall high or low expression in
the majority of diseased valves and a small number
where expression was high or low only in CKCS. This
was consistent with the sample-to-sample analysis and
suggested that there were indeed sets of differentially
expressed genes that distinguished the normal and dis-
eased valves. The largest component of the network
graph is shown in Fig. 2a and clusters that demonstrate
differences between diseased and normal valves are
shown in Fig. 2b. Histograms indicate the average ex-
pression of genes in the clusters; gene lists for these
clusters and enlarged images of the histograms are pre-
sented in Additional file 1, Table S1.
Having identified clusters that showed expression pat-
terns associated with disease status (Fig. 2b), we
searched them for proliferation genes and found that
there was no association of cell division markers [31]
with disease or breed status, suggesting that perturbed
patterns of cell division may not be a consistent feature
of MMVD in either CKCS or other breeds. In addition,
mitochondrial genes [32, 33] were spread amongst a
number of clusters and showed no association with
breed or disease status, suggesting that mitochondrial
dysfunction does not make a major contribution to
MMVD. Since immune response had been identified as
altered in previous studies [18, 19] we also looked for
clusters associated with changes in expression of im-
mune/inflammatory genes [34]. Consistent with reports
of an immune involvement in MMVD, a small number
of macrophage and T-cell genes were in cluster011
(higher in all diseased valves; Additional file 1, Table
S1). However, most of the genes associated with immune
function were found in different clusters and showed no
correlation with disease or breed status.
As mentioned above, the majority of the clusters had
expression patterns driven by a single sample, and would
not reveal functions likely to be informative for MMVD
aetiology in general. We therefore subjected only the
genes within the disease associated clusters shown in
Fig. 2b to enrichment analysis using DAVID (see
Methods). Cluster002, which was a large group of genes
apparently down-regulated in CKCS, was analysed separ-
ately, while the genes in other down-regulated clusters
and the up-regulated clusters were each pooled because
they showed similar average expression patterns and
were close to each other in the network. This ensured
that the groups were of sufficient size for meaningful
analysis (Additional file 1, Table S1).
For Cluster002, which contained genes that were lower
in CKCS valves than those from other diseased dogs or
normal dogs, there was enrichment of Biological Process
(BP) terms related to muscle structure and activity, car-
diac conduction and calcium ion release. For Cellular
Component (CC), terms related to sarcolemma were
enriched. The top 10 GO terms are presented in Add-
itional file 1, Table S2. For the group of clusters in which
genes were generally down-regulated in all diseased
valves, DAVID GO enrichment analysis found enrich-
ment for extracellular matrix and cell surface terms. For
the clusters which contained genes that were up-
regulated in diseased valves, there was enrichment of
GO terms related to inflammatory response, monocyte
chemotaxis and extracellular exosome.
Comparison of CKCS diseased valve transcriptome with
normal valve transcriptome
The BioLayout analysis identified groups of genes that
appeared to be up- or down-regulated in diseased valves,
as well as a cluster of genes that were down-regulated
only in CKCS valves. The analysis revealed that there
were many genes showing idiosyncratic sample-specific
expression patterns, which may have concealed some
meaningful differences and resulted in the paucity of sig-
nificant GO term enhancement. We therefore generated
lists of differentially expressed genes (DEG) with the
Affymetrix Transcription Analysis Console, using a one-
way between-subject ANOVA (unpaired), which takes
into account variance among samples in calculating the
p-value and determines a false discovery rate (FDR) to
allow for multiple comparisons. A threshold FDR q-
value of 0.05 was used in the analyses.
To confirm the findings of the GCN analysis, an
initial comparison was made between CKCS diseased
valves and normal valves. Using a fold change of at
least 1.5 in either direction and an FDR q-value <
0.05, transcripts detected by 755 probesets were dif-
ferentially expressed, representing 599 annotated
genes and a number of unannotated probesets. Two
hundred and seventy-one annotated genes were
higher in CKCS (up-regulated) and 328 genes were
lower in CKCS (down-regulated) (Fig. 3a, full list of
genes in Additional file 2, Table S3). These 599 genes
were analysed using DAVID GO enrichment analysis.
For the down-regulated genes, there was enrichment
of similar GO terms to those found for Cluster002 of
the GCN analysis, as shown for the top 10 enriched
GO terms in Additional file 2, Table S4. The enriched
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GO terms were related to cardiac muscle cell func-
tion and structure and calcium channel activity. For
up-regulated genes terms related to immune response
and ERK1/ERK2 activity were listed.
Comparison of CKCS diseased valve transcriptome with
transcriptome of diseased valves from other breeds
The sample-to-sample analysis suggested that gene ex-
pression in CKCS diseased valves was different from that
Fig. 2 Gene-to-gene analysis using BioLayout, showing relationship between genes. Nodes (spheres) represent genes and edges (lines) show
correlation of greater than 0.90 between gene expression patterns across all samples, allowing the similarity of gene expression patterns across all
samples to be examined. a. The largest element in the graph created by BioLayout from the expression profiles of genes across the breeds and
disease status. Nodes of the same colour were allocated to the same expression cluster by the MCL clustering algorithm (inflation value 1.7)
because they have similar expression patterns in the samples. b. Clusters showing differential expression according to sample type. The network
layout is the same as for Fig. 2a but only the apparent differentially expressed clusters are shown. Histograms surrounding the network graph are
coloured the same way as the nodes of that cluster and show the average expression of genes in the cluster. X axis shows the disease status of
the valve; upper bar shows the grade of disease (Green − normal valves; Orange – Grade 3 diseased valves; red – Grade 4 diseased valves); lower
bar shows the breed and valve status (green − normal valves; blue − non-CKCS diseased valves; red − CKCS diseased valves). Y axis shows
average expression. Gene lists for these clusters and enlarged images of the histograms are presented in Additional file 1
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in diseased valves from other breeds. Therefore we next
compared the two sets of diseased valves. One hundred
and sixty one annotated genes were differentially
expressed, 27 with higher expression in CKCS valves
than other diseased valves and 134 with lower expres-
sion in CKCS valves (Fig. 3b, Additional file 3, Table
S5). For the genes that were lower in CKCS diseased
valves than other breed diseased valves, the GO terms
were similar to those distinguishing CKCS from normal
valves, with an emphasis on cardiac muscle structure
and function (Additional file 3, Table S6). A single GO
term was enriched for the genes that were higher in
CKCS valves than other breed diseased valves.
Eighty-one genes were downregulated in CKCS dis-
eased valves compared both to normal valves and to dis-
eased valves from other breeds, suggesting that these
Fig. 3 Volcano plots of differentially expressed genes comparing CKCS, non-CKCS, all diseased valves and normal dog valves. Red dots represent
genes that show increased expression, green represent genes that show decreased expression and grey dots represent genes which did not pass
the differential expression criteria. The X-axis shows fold change value and the Y-axis shows p-value. Central vertical line shows 0 fold change
with negative fold changes on the left and positive fold changes on the right. Only fold changes of at least ±1.5 are shown. a CKCS vs Normal
with FDR correction (q-value < 0.05). b non-CKCS vs CKCS with FDR correction (q-value < 0.05). c Non-CKCS vs Normal with no FDR correction (p-
value < 0.05). d All diseased valves vs Normal with FDR correction (q-value < 0.05). The table shows numbers of DEG which met the stringent
criteria (fold change ±1.5, FDR q-value < 0.05) are shown for each comparison
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represent a breed-specific effect, which may or may not
be related to the disease. Similar GO terms were
enriched in this set of down-regulated genes, primarily
terms associated with cardiac development and function
(Additional file 4, Table S7 and Table S8). This suggests
that CKCS have abnormalities of expression of genes in-
volved in cardiac development and function which may
be related to the early onset of MMVD. Nineteen genes
were up-regulated in CKCS compared with both normal
valves and diseased valves from other breeds. A single
GO term was enriched, as for the comparison between
CKCS and other breed diseased valves (Additional file 4,
Table S8).
Comparison of diseased valve transcriptome with normal
valve transcriptome
The BioLayout sample-to-sample network showed that
the non-CKCS diseased valves were close in gene ex-
pression pattern to the normal valves (Fig. 1c), and there
were no significant DEGs when comparing these two
groups at the stringency used for the other comparisons
(FDR q-value < 0.05). Consistent with this, the volcano
plot for this comparison showed that the fold changes
were lower, the p-values were higher and the genes were
less scattered than in the other plots, supporting the ob-
servation that the normal and non-CKCS diseased valves
were closer in gene expression pattern than either were
to the CKCS valves. Relaxing the stringency of the ana-
lysis (unadjusted p < 0.05, no FDR correction; Fig. 3c)
showed that there were 278 differentially expressed
genes, of which 166 were higher in the diseased valves
and 112 were lower. For this lower stringency set, there
were several enriched GO terms that overlapped with
the set produced comparing CKCS and normal valves.
The network cluster analysis showed that there were a
number of genes where the majority of diseased valves
were different from the normal valves. To examine fur-
ther whether there were genes that were differentially
expressed in both sets of diseased valves, we generated a
list of DEGs comparing all diseased valves with normal
valves (FDR q-value < 0.05, fold change at least 1.5 in ei-
ther direction) (Additional file 5, Table S9). One hun-
dred and six genes were differentially expressed, 50 with
lower expression and 56 with higher expression in dis-
eased valves than normal valves (Fig. 3d). Enrichment of
GO terms for the down- and up-regulated genes is
shown in Additional file 5, Table S10. For the up-
regulated genes, terms related to skeletal system and
mesenchyme migration were found, consistent with the
increased EndoMT in the diseased valve. For the down-
regulated genes, the term calcium ion binding was
enriched, supporting the idea that calcium homeostasis
is perturbed in MMVD.
Pathway analysis of differentially expressed genes
The online Ingenuity Pathway Analysis tool (IPA) in-
cludes a database of genes/proteins in pathways built
mostly from human and laboratory animal data. Analysis
with IPA identified 77 canonical pathways when com-
paring the transcriptome of normal valves to CKCS
valves, 28 when comparing CKCS valves to non-CKCS
diseased valves and 56 when comparing all diseased
valves with normal valves. The top three pathways for
each comparison are shown in Table 2 and the top four
upstream regulators for each dataset comparison, with
their associated Z-score indicating predicted activation
or inhibition, are shown in Table 3. Of particular note
are changes in calcium signaling in the CKCS compared
to both normal and non-CKCSs datasets (Tables 3 and
4). For calcium signaling there were 23 DEGs (17 lower
in CKCS) comparing CKCS with normal, 10 DEGs (all
lower in CKCS) comparing CKCS and non-CKCS and 5
DEGs (1 lower in diseased valves) comparing all diseased
valves to normal. Shared DEGs included genes associ-
ated with calcium homeostasis, non-canonical TGFβ sig-
nalling pathways (ERK1/2, IP3, RhoGTPase),
cytoskeleton, muscle contraction (including cardiomyo-
cytes), and the calcineurin/NFAT (nuclear factor of acti-
vated T cells) pathway. IPA analysis also found that
hepatic fibrosis/hepatic stellate cell activation was chan-
ged in CKCS and all diseased valves compared to nor-
mal. This association was also found in the lower
stringency analysis of normal valves with non-CKCS dis-
eased valves. In the hepatic fibrosis/hepatic stellate cell
activation gene dataset DEGs included genes associated
with collagen homeostasis, cytoskeleton and cell growth
and differentiation. Fibroblasts from different organs
have different phenotypes and the relevance to mitral
VICs is unclear.
A curious observation comparing CKCS to normal
was IPA predicted up-stream regulator analysis
tended to be activated (positive activation Z-score in
IPA), but the predicted regulators tended to be inhib-
ited in CKCS relative to non-CKCS (negative activa-
tion Z-score). However, these differences in
themselves are not the main biological interest, but
which regulators are predicted to be affected and
whether activated or inhibited. For CKCSs compared
to normal there were 1831 molecules with F2 (pro-
thrombin) signalling pathway having the strongest as-
sociation, but also TNF and TGFβ1 signalling
featured in the top four upstream regulators. Compar-
ing the two disease datasets, 377 molecules were asso-
ciated, with the top upstream regulator being
myocyte-specific factor 2c (MEF2C). The down-stream
effects, as predicted by IPA, for TGFβ1, MEF2C and
F2 (prothrombin) are shown in Additional file 6, Fig-
ure S1 A-C.
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The top five disease and function annotations were
assigned to the datasets by IPA and an illustrative graphical
representation is shown in the Additional file 7, Table S11
and Figure S2. Comparing the datasets, these annotations
generally matched to the same general themes, but identify-
ing the subtle differences required examination of the
graphic representations, with the illustrative example for
Skeletal and Muscular Disorders and Developmental Dis-
order and Hereditary Disorder, comparing CKCS and non-
CKCS shown in Additional file 7, Figure S2.
Discussion
We have recently shown that the transcriptome of
the mitral valve changes as MMVD advances from
the normal valve to the severely diseased Whitney
grade 4 valve [21]. We found that TGFβ was the
dominant signalling pathway controlling
pathogenesis, consistent with findings in cultured
valve interstitial cells [22]. The current study has
identified gene expression differences in mitral valves
of CKCS with severe valve pathology compared to
valves from age and disease severity-matched non-
CKCS dogs. These differences may be associated
with the earlier onset of severe MMVD in the CKCS
or may be an unrelated feature of the breed. Given
the high breed-specific prevalence of MMVD in
CKCS and the involvement of many of the pathways
identified in the development and function of the
cardiovascular system, it is possible that these differ-
ences influence the aetiology of MMVD in CKCS, al-
though the effects of these pathways on MMVD
development will need to be confirmed with func-
tional studies. However, there are several limitations
to the study. Firstly, all diseased dogs were older
Table 2 Top three canonical pathways associated with each dataset. The number of genes altered in each pathway as well as the
total number of genes changed in each pathway is shown
Analysis Canonical Pathway Up Down Gene changes in pathway p-value
CKCS vs Normal Calcium signaling 6 17 23/179 7.943E-11
Hepatic fibrosis/Hepatic stellate cell activation 8 12 20/183 2.988E-08
Axonal guidance signaling 11 16 27/452 1.995E-05
CKCS vs non-CKCS Calcium signaling 0 10 10/179 6.456E-06
LPS/IL-1 mediated inhibition of RXR function 2 5 7/168 0.0009
Gluconeogenesis I 0 3 3/22 0.001
All diseased vs normal Paxillin signaling 3 1 4/108 0.0006
Calcium signaling 4 1 5/179 0.0009
STAT3 pathway 4 0 4/135 0.001
Of note is change in calcium signalling comparing CKCS to the other two data sets highlighted in bold. The P-value score shows the strength of association of the
gene list to the pathway
Table 3 The top four upstream regulators associated with the differentially expressed genes lists for each dataset
Analysis Upstream regulator Molecule type Activation Z-score P-value
CKCS vs Normal F2 Peptidase 1.503 2.2E-12
TNF Cytokine 1.892 2.18E-11
AGT Growth factor 2.018 1.15E-10
TGFB1 Growth factor 1.486 9.03E-10
CKCS vs non-CKCS MEF2C Transcription regulator −3.087 1.11E-09
MYOCD Transcription regulator −2.768 1.33E-07
2,3 butanedione monoxime Chemical drug −1.4 3.71E-07
DNMT3A Enzyme 1.667 6.27E-07
All diseased vs Normal NOTCH4 Transcription regulator 1.777 6.33E-10
MED28 Other −1.957 6.32E-09
HEY1 Transcription regulator −1.547 2.61E-08
MYCOD Transcription regulator 2.571 4.6E-08
For each upstream regulator, the molecule type, Z-score and P-value are given. The activation Z-score is used to infer likely activation states of upstream
regulators based on comparison with a model that assigns random regulation
directions. https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/
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than the normal dogs and differences could simply
be due to an age effect unrelated to MMVD status.
Secondly, the other breed diseased valves and the
normal valves came from several breeds of dogs, in-
cluding some mixed breed animals, and the differ-
ences from CKCS valves could reflect the greater
genetic similarity of the CKCS in contrast to the
greater admixture of the other dogs [35]. Examining
gene expression in normal and diseased age-matched
CKCS valves would be ideal, but obtaining healthy
valves from elderly dogs is not feasible due to the
ubiquity of the disease in older CKCS. Similarly,
comparison of normal valves from young CKCS with
diseased valves from older CKCS would be interest-
ing, but our study relies on samples from client
owned dogs, and young CKCS with healthy valves
are rarely euthanased. Gene expression could also be
examined in age matched valves of another MMVD-
predisposed breed with a similar level of genetic di-
versity. However the early onset and high prevalence
of MMVD in CKCS means that it would be difficult
to find a matched breed. Nonetheless, it is possible
to draw some conclusions from our study.
Among the genes that had lower expression in CKCS
valves than non-CKCS diseased valves or normal dog
valves were a range of cardiomyocyte-related genes in-
cluding CASQ2 (calsequestrin), TNNI3 (troponin I
type3) and RYR2 (ryanodine receptor 2), and various
myosin genes. A striking feature of the GO term analysis
was the reduced expression of genes involved in cardiac
development and function in the CKCS valves. There
may be a more general effect on the cardiovascular sys-
tem of the CKCS. There were clear similarities in gene
enrichment analysis and GO terms comparing both dis-
eased groups to normal, including genes recognised as
hallmarks of canine MMVD, such as ACTA2 (encoding
α-SMA) and HTR2B (encoding 5HT2B receptor) [18,
27]. This likely reflects the global gene signature typical
of MMVD where there is aberrant extra-cellular matrix
remodelling as a consequence of changes in TGFβ sig-
nalling [18, 19, 21, 36]. The other shared DEGs, in par-
ticular those coding for the myosin heavy chains and
growth factors, suggest the involvement of TGFβ non-
canonical signalling pathways affecting down-stream sig-
nals including MEK, ERK1/2, IP3 and RhoGTPase [37].
All these pathways have regulatory roles in stress fibre
formation, EndoMT and apoptosis, and can be induced
by the TGFβs, 5HT and Ca++ signalling. TGFβ1 was one
of the top upstream regulators in the CKCS valves,
which would suggest TGFβ1 is an important driver of
MMVD pathogenesis in dogs.
In the previously published study comparing diseased
CKCS valves with normal valves using the Affymetrix
Canine Gene 1.0ST Array, similar changes in gene ontol-
ogy and gene networks were found, including regulation
of EndoMT and caveolar-mediated endocytosis, but cal-
cium signalling as a dysregulated canonical pathway was
not reported [18]. In that study IPA identified only 33
canonical pathways compared to 77 in the current study.
The identification of the hepatic fibrosis/hepatic stel-
late cell activation pathway in diseased valves might ap-
pear problematic to explain given that it refers to
hepatic pericytes and that fibroblast phenotypes differ
between tissues. However, this term encompasses signal-
ling pathways relevant to the broad interstitial/myofibro-
blast cell lineage, which activated myofibroblasts, and
this observation fits with what is already known about
MMVD and the role of activated myofibroblasts in ECM
remodelling and disease pathogenesis [23, 38–40]. Of
interest was the identification of GO terms and canon-
ical pathways and upstream regulators exclusive to the
CKCS group. These included the canonical pathway cal-
cium signalling and upstream regulator F2 (prothrom-
bin), and various cardiovascular and immune-related
GO terms. The potential role of immunity in MMVD
might be difficult to explain as there is currently no evi-
dence of inflammatory cell involvement in canine
MMVD [23, 38]. There is however, evidence for
Table 4 Gene expression changes associated with calcium signalling and hepatic fibrosis/hepatic stellate cell activation canonical
pathways
Datasets Gene name
Calcium Signalling
CKCS vs Normal ACTA1, ACTA2, AKAP5, ATP2A2, CASQ, GRIN2A, GRIA3, HDAC9, MYH7, MYH7B, MYH1, MYL4, NFATC1, RCAN2, RYR2, SLC8B1,
TNNI3, TPM2, TRDN
CKCS vs non-CKCS ACTA1, ATP2A2, CACNA1G, CACNA1H, CASQ2, MYH7, RCAN2, SLC8B1, TNNI3, TRDN
All diseased vs
Normal
ACTA2, HDAC9, MYH11, TPM2, TRPC5
Hepatic fibrosis/hepatic stellate cell activation
CKCS vs Normal ACTA2, CCL5, COL6A3, EDNRA, IL1RL1, KDR, LAMA1, MYH7, MYH11, MYH7B, MYL4, NGFR, PDGFR, SERPINE1,
All diseased vs
Normal
ACTA2, COL11A2, MYH11, SERPINE1
Down-regulated genes are shown in bold
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inflammatory changes in the human MMVD and the
CKCS breed does appear to be pre-disposed to a range
of inflammatory conditions [20, 23, 38, 41, 42]. Network
analysis using IPA has identified genes associated with
“inflammation”, but this likely refers to pathways shared
with other functions such as cell signalling, cell migra-
tion and EndoMT, since many of the same genes can be
associated with immune responses [18, 19, 27]. Further-
more, expression of interleukins, chemokines and
growth factors can be affected by the same up-steam
regulators that control TGFβ signalling pathways.
F2 (prothrombin) was identified as the top upstream
regulator in diseased CKCS valves, compared to normal
valves, and IPA predicted pathway activation, with ef-
fects on a relatively large range of genes in the extra-
cellular space, plasma membrane, cytoplasm and nu-
cleus, including ACTA2 (Additional file 6, Figure S1 C).
While typically associated with blood coagulation, pro-
thrombin/thrombin also has a pro-inflammatory role
and down-stream regulatory effects on endothelial,
smooth muscle and fibroblast (interstitial) cells, and can
both induce and inhibit TGFβ1 signalling in a context
specific manner [43]. However, the reported CKCS pre-
disposition to platelet dysfunction and macro-
thrombocytopenia is well recognised, and macro-
thrombocytopenia has been associated with early
MMVD development in humans [7, 10, 12]. Considering
these effects, and what is known about MMVD path-
ology, a potential role for prothrombin/thrombin in
CKCS MMVD pathogenesis can be postulated, possibly
through platelet interaction and enhanced 5HT signal-
ling [15, 44, 45].
Changes in expression of cardiomyocyte-related
genes were found in the CKCS dataset, including MB
(myoglobin), CASQ2 (calsequestrin2), NEBL (nebul-
ette) and various actin and myosin genes. While the
changes in calcium signalling and MEF2C expression
might reflect global changes in cell signalling and
ECM remodelling, they might also be due to changes
in the cardiomyocyte content of the tissue samples.
Care was taken to ensure the same dissection proto-
col, removing atrial myocardium and the annular at-
tachment, was used for each valve. Nevertheless, in
whole valve samples atrial cardiomyocytes can be
found extending a variable distance into the valve,
and this extent declines in diseased leaflets [46–49].
Morphological studies are needed to determine if
there are differences in CKCS valve myocardium con-
tent compared to non-CKCS that may explain some
of these transcriptomic differences. Indeed, there is
emerging interest in valve contraction mechanics and
how this is affected by or contributes to the diseased
state, and in this context the relative contribution of
valve cardiomyocytes needs to be considered [50].
The myocardial gene MEF2C (the transcription factor
myocyte-specific factor 2c) was the top upstream regula-
tor when CKCS were compared to non-CKCS diseased
valves and IPA predicted pathway inhibition, with effects
on a relatively small group of cytoplasmic and nucleus
genes including CASQ2 (Additional file 6, Figure S1 B).
MEF2C is important in myogenesis and cardiomyocyte
development, regulating cardiac alpha-actin and alpha
myosin heavy chain [51]. However, as a transcription
factor, it also regulates the expression of the ECM pro-
tein cartilage link protein 1 (HAPLN1 gene) in VICs dur-
ing valve development and has a wide range of other
effects, including in the EGF/EGFR and the apelin sig-
nalling pathways, that contribute to non-canonical
TGFβ1 signalling, proper development of megakaryo-
cytes and platelets, and cell migration and differentiation
[51].
Calcium signalling was identified as the top canonical
pathway in the CKCS dataset, and transcription factors
in the top upstream regulator list and GO terms related
to cardiac muscle contraction, control and differenti-
ation, were down-regulated in CKCS diseased valves.
Understanding how down-regulation of cardiac muscle,
smooth muscle-related and calcium binding pathways
impact on CKCS MMVD may provide insight into the
early-onset pathogenesis in CKCS. For example, 5HT
signalling through Gq protein-coupled receptors (such
as 5HTR2B) causes an influx of calcium into the cell as
part of 5HT downstream signalling pathways, and there
is consistent and significant increased 5HTR2B expres-
sion in the canine mitral valve transcriptome [15, 18, 19,
27]. In the light of the data presented here, the recent
identification of the beneficial effect of the calcium
sensitizer and positive inotrope pimobendan in protect-
ing against progression to heart failure is an interesting
finding [52].
The results of this study provide hints about the genes
in which variants might be related to the severe early
onset of MMVD in CKCS. To validate these results a
number of approaches could be taken. As part of on-
going studies we are examining valve morphology to
quantify the any differences in cardiomyocyte content in
the CKCS. Since it is not possible to obtain samples
from young/healthy client-owned dogs, further investiga-
tion of other breeds susceptible to MMVD could deter-
mine if changes seen are breed-specific. We have
validated, and currently are using, a robust primary VIC
cell culture system for which we have transcriptomic
data for cells derived from non-CKCS, and this could be
used to examine further CKCS-specific differences [22,
53]. Loss/gain of function studies for specific genes of
interest could be undertaken to see if they affect the
valvular cell phenotype. Lastly, more targeted examin-
ation of the calcium signalling and other pathways
Markby et al. BMC Veterinary Research          (2020) 16:350 Page 10 of 14
identified could be undertaken, examining both gene
and protein expression in CKCS valve tissue and cell
cultures.
The notable limitations of this study include the small
sample size, the age disparity between normal and dis-
eased animals and the genetic dissimilarity of the CKCS
to the other dogs. Difficulties in age-matching are an ac-
cepted confounding factor for MMVD research consid-
ering the ubiquity of valve pathology changes in all
elderly dogs, some of which may be associated with
healthy aging. CKCS have a distinct genetic profile [35]
and this may account, in part, for the disparity in DEG
numbers comparing CKCS with the two other groups.
Studies are needed to determine whether this differential
gene expression underlies the susceptibility of the CKCS
to develop the disease sooner and to progress more rap-
idly than other dogs, bearing in mind that they might
not have life-long differential expression [24]. Lastly, the
more stringent FDR analysis could not be applied to the
normal and non-CKCS analysis. This likely reflects their
genetic heterogeneity and difference in baseline expres-
sion of genes, and in that circumstance is an accepted
limitation of genomic profiling, with similar problems
found when examining human populations [20, 54].
Relaxing the strict FDR threshold revealed candidate
genes and pathways that were enriched in this compari-
son, consistent with the observations of the higher strin-
gency comparisons and supporting the need for further
analysis of these candidates.
Conclusions
This study has identified interesting differences in the
transcriptomic profile of CKCS mitral valves compared
with non-CKCS valves, all with severe MMVD. In par-
ticular we have identified differences in expression for
genes associated with cardiomyocytes including CASQ2,
TNNI3 and RYR2. Studies are needed to determine if
these gene expression changes simply reflect differences
in valve cardiomyocyte density, which might then affect
valve mechanics, valve coaptation and pathology devel-
opment. Alternatively, the gene expression changes may
impact in a CKCS-specific manner on valve cell function
and ECM synthesis and remodelling. These results pro-
vide the basis for further studies to examine the specific
gene and signalling pathway changes and their contribu-
tion to disease pathogenesis, and any breed-specific
susceptibility.
Methods
Aims, design and setting of the study
The aim of this study was to determine whether expres-
sion patterns were different in CKCS diseased mitral
valves compared to non-CKCS dogs. Valve samples were
collected from dogs were presented to the Hospital for
Small Animals, Royal (Dick) School of Veterinary Stud-
ies, the University of Edinburgh. Euthanasia had been re-
quested by the owners because of terminal conditions or
intractable conditions which impacted severely on their
pets welfare. No dogs were euthanased for the purpose
of the study and all tissue was collected and used with
full informed written owner consent, and with institu-
tional ethical approval (Veterinary Ethics in Research
Committee).
Tissue samples
Details of the dogs used in this study are shown in Table
1. All valves were scored by two of the authors (GRM &
BMC). Diseased valves had changes typical of Whitney
grade 3 or 4 (severe to very severe disease) [2]. Normal
dogs had no evidence of any disease, and mitral valves
were considered to be normal on gross inspection.
Valves were collected shortly after euthanasia as previ-
ously described (intra-venous pentobarbitone overdose)
[18], washed gently in warm phosphate buffered saline
(PBS), immediately placed in RNAlater (Invitrogen USA)
and stored for future RNA extraction [18]. Any attached
atrial myocardium, annulus and chordae were removed,
and the remaining whole valve was used for RNA extrac-
tion. Dogs with advanced disease were on a combination
of standard medication for the treatment of congestive
heart failure and any effect this might have on valve gene
expression is unknown.
RNA extraction, quantification, quality control and
transcriptomic profiling
RNA was extracted from the whole valve (anterior and
posterior leaflet) following a standard protocol as previ-
ously described [18]. RNA extraction and DNA digestion
were performed using the Qiagen RNeasy mini kit (Qia-
gen, Germany) according to the manufacturer’s instruc-
tions. Total RNA was eluted in 30 μl nuclease free water
and stored at − 70 °C. Quantification of RNA was per-
formed by spectrophotometry in a NanoDrop™1000
(Thermo Scientific), measuring absorbance at 260 nm
wavelength in 1 μl of extracted RNA solution, and ab-
sorbance ratios of 260/280 and 260/230 were analysed to
check for impurities. The ratio of ribosomal 28S to 18S
RNA was measured to assess for degradation using the
Agilent RNA Screentape system and Agilent 2200 tapes-
tation analyser (Agilent Technologies, USA) according
to the manufacturer’s instructions. RNA integrity num-
ber (RIN) was then calculated with RIN ≥7 being taken
as optimal for transcriptomic analysis. The Affymetrix
GeneChip™ Canine Gene 1.1 ST Array plate was used
for transcriptomic profiling. Arrays were run by Edin-
burgh Genomics, University of Edinburgh, UK. The
Affymetrix Expression Console (Build 1.4.1.46) was used
to normalise the data from the generated .cel files and
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for quality control. An annotated file of expression re-
sults was generated and filtered for all genes with a max-
imum relative expression level of less than 15, consistent
with the background level detected during the quality
control process. This filtered set of genes was used for
subsequent expression and enhancement analysis.
Network analysis and functional clustering of canine
valve samples
The network analysis tool BioLayout-3.4 (http://biolay-
out.org) [55] was designed for the visualisation and ana-
lysis of network graphs from large datasets. BioLayout
clusters data based on similarity of gene expression pat-
tern with nodes representing a data point and edges the
relation between nodes, using the Fruchterman-
Rheingold algorithm. BioLayout was used to examine ex-
pression of genes across the grades of valve disease. In a
sample-to-sample analysis (similar to a principal compo-
nents analysis) nodes represent samples and the network
layout shows the similarity of samples based on the ex-
pression of all genes in the sample. For the sample-to-
sample comparison of mitral valve transcriptomic data
using the filtered set of genes (relative expression ≥15 in
at least one sample), a Pearson correlation coefficient of
r ≥ 0.98 was used as it was the highest that included all
samples. Meta-data (grade of disease, age, sex, breed) as-
sociated with the dataset were then examined to see if
any parameter accounted for the network layout.
Gene-to-gene analysis with BioLayout was used to
generate a gene co-expression network (GCN) where
nodes represent genes and edges the correlation between
them at or above the chosen threshold. The network lay-
out shows the similarity of gene expression patterns
across all samples. For the network layout a high strin-
gency threshold r value of 0.9 was used. Subsequent ana-
lysis using the Markov clustering algorithm (MCL) [56]
identified groups of highly connected genes within the
elements of the network. The inflation value was set at
1.7 to control granularity of the clusters.
Differentially expressed genes
The Affymetrix transcriptome analysis console (TAC,
version 3.1.0.5) was used to perform unpaired one-way
analysis of variance and detect differentially expressed
genes (DEG). DEG lists were created for genes with a
fold change of > 1.5 or < − 1.5. A Benjamini-Hochberg
false discovery rate (FDR) correction (Q-value < 0.05)
was applied. Annotation information for un-annotated
transcript probes was found in TAC through an inter-
face with the Affymetrix online browser. Gene lists were
then used for gene enrichment analysis.
Reverse transcriptase quantitative PCR (RT-qPCR) was
undertaken using the Takyon 2X low Rox SYBR green
mastermix dTTP blue (Eurogentec, Belgium) to validate
the microarray data and included the following genes;
ACTA2, HTR2B, TAGLN, ACTG2, SLIT3, CDKN2A,
SLC10A6, CILP, MMP12, ADAMTS5 and ADAMTS19.
Primer sequences are shown in Table 5. RT-qPCR
showed equivalent direction and magnitude to the re-
sults with the microarray for these genes.
Gene enrichment analysis
Gene lists from the network analysis and the differen-
tially expressed gene lists were analysed with the Data-
base for Annotation, Visualisation and Integrated
Discovery (DAVID v6.8; http://www.david.ncifcrf.gov)
[57, 58]. DAVID collates the biological processes that
are associated with genes in a list using the gene ontol-
ogy (GO) terms. Gene lists deriving from differential ex-
pression analysis or BioLayout clustering were uploaded
to DAVID for analysis. GO terms were selected for bio-
logical processes (GOTERM_BP_DIRECT), cellular
components (GOTERM_CC_DIRECT) and molecular
function (GOTERM_MF_DIRECT). The reference list
was from Canis lupus familiaris and enrichment was
assessed using Fisher’s exact test.
In addition, differentially expressed gene lists were
uploaded, with related fold change, to the online Ingenu-
ity Pathway Analysis (IPA) server (Qiagen, Germany)
where core analysis was performed. This compared the
submitted genes to all published literature and assigned
reported attributes and pathways to them. From these
canonical pathways, upstream regulators (activated,
inhibited or activation state unknown) disease and bio-
logical functions, as well as other factors, were inferred
by the software. These results were generated based on
the number of genes in the submitted list that matched
the genes reported in the literature to be involved in a
certain process, with a statistical association calculated.
Core analysis was performed with default settings on fil-
tered gene sets.
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